Novo Holdings

Novo Holdings is a holding and investment company managing the assets and wealth of the Novo Nordisk Foundation. Its primary purpose is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Foundation. As the controlling shareholder of Novo Nordisk and Novonesis (formerly Novozymes), Novo Holdings manages a broad investment portfolio encompassing equities, bonds, real estate, infrastructure, and private equity assets. A significant portion of their investment strategy focuses on life science companies across all stages of development. Their investment approach is characterized by a long-term perspective and a commitment to responsible investing. Novo Holdings aims to be a catalyst for change by investing in companies that address pressing challenges related to human and planetary health. This includes a specific focus on the green transition, seeking out promising discoveries that can be translated into applicable biosolutions. The firm operates with values-driven principles, striving for high performance with respect and responsibility, and leading by example. Within life sciences, Novo Holdings invests through Seed, Venture, Growth, Principal Investments, and Asia teams. They also have a dedicated Planetary Health Investments team focused on biotechnology solutions for environmental challenges. The firm actively engages with its portfolio companies, providing support to help them deliver on their promises and achieve meaningful, sustainable impact. Their overall strategy balances a diversified capital investment allocation with a significant focus on direct investments in strategically aligned companies. Novo Holdings aspires to be a leading responsible investor, recognized for delivering strong financial returns and positive societal impact. The firm leverages its deep scientific knowledge, operational expertise, and global network for the benefit of its portfolio companies. Their evergreen capital allows for a longer-term investment horizon, fostering true partnerships aimed at enabling portfolio companies to fulfill their full potential.

Life Sciences, Planetary Health (biosolutions, industrial biotechnology), Clinical Diagnostics, Biologics Supply Chain, Healthcare IT, Equities, Bonds, Real Estate, Infrastructure, Private Equity

Thematische Schwerpunkte und Zielmarktsegmente von Interesse.